{"DataElement":{"publicId":"6272113","version":"1","preferredName":"Malignant Neoplasm Therapeutic Procedure Plan Description Stratification Code","preferredDefinition":"Stratification code representing a type of therapy.","longName":"6272106v1.0:6272108v1.0","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"6272106","version":"1","preferredName":"Malignant Neoplasm Therapeutic Procedure Plan Description","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._To devise, contrive, or form in design._A written or verbal account, representation, statement, or explanation of something.","longName":"6272103v1.0:6272104v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"6272103","version":"1","preferredName":"Malignant Neoplasm Therapeutic Procedure","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C9305:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BBA6ED8-0145-6419-E053-F662850A9D69","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6272104","version":"1","preferredName":"Plan Description","preferredDefinition":"To devise, contrive, or form in design.:A written or verbal account, representation, statement, or explanation of something.","longName":"C25619:C25365","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plan","conceptCode":"C25619","definition":"To devise, contrive, or form in design.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BBA6ED8-0156-6419-E053-F662850A9D69","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BBA6ED8-0167-6419-E053-F662850A9D69","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6272108","version":"1","preferredName":"Therapeutic Procedure Stratification Code","preferredDefinition":"Stratification code representing a type of therapy.","longName":"6272108v1.0","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1","valueDescription":"Cytotoxic (with or without immunotherapy or targeted therapy)","ValueMeaning":{"publicId":"6272109","version":"1","preferredName":"Cytotoxic (with or without immunotherapy or targeted therapy)","longName":"6272109","preferredDefinition":"Cytotoxic (with or without immunotherapy or targeted therapy)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9D9A6-C70B-2131-E053-F662850A680C","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6BB9D9A6-C724-2131-E053-F662850A680C","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","deletedIndicator":"No"},{"value":"2","valueDescription":"Immunotherapy Alone","ValueMeaning":{"publicId":"6272110","version":"1","preferredName":"Immunotherapy Alone","longName":"6272110","preferredDefinition":"Immunotherapy Alone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9D9A6-C72E-2131-E053-F662850A680C","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6BB9D9A6-C747-2131-E053-F662850A680C","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","deletedIndicator":"No"},{"value":"3","valueDescription":"Targeted Therapy Alone","ValueMeaning":{"publicId":"6272111","version":"1","preferredName":"Targeted Therapy Alone","longName":"6272111","preferredDefinition":"Targeted Therapy Alone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9D9A6-C751-2131-E053-F662850A680C","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6BB9D9A6-C76A-2131-E053-F662850A680C","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","deletedIndicator":"No"},{"value":"4","valueDescription":"Immunotherapy and Targeted Therapy","ValueMeaning":{"publicId":"6272112","version":"1","preferredName":"Immunotherapy and Targeted Therapy","longName":"6272112","preferredDefinition":"Immunotherapy and Targeted Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9D9A6-C774-2131-E053-F662850A680C","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6BB9D9A6-C78D-2131-E053-F662850A680C","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","deletedIndicator":"No"},{"value":"2","valueDescription":"Combination","ValueMeaning":{"publicId":"2673711","version":"1","preferredName":"Combination","longName":"2673711","preferredDefinition":"A collection of things that have been assembled together to form a new whole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combination","conceptCode":"C61517","definition":"A collection of things that have been assembled together to form a new whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38221109-1174-1014-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-20","endDate":null,"createdBy":"UMLLOADER_BCR","dateCreated":"2007-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1373D4B-2E86-0B69-E053-4EBD850AB55D","beginDate":"2021-04-30","endDate":null,"createdBy":"KEARNSD","dateCreated":"2021-04-30","modifiedBy":"ONEDATA","dateModified":"2021-04-30","deletedIndicator":"No"},{"value":"1","valueDescription":"Single Agent","ValueMeaning":{"publicId":"3366701","version":"1","preferredName":"Single Agent","longName":"3366701","preferredDefinition":"Not accompanied by another or others.: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5111-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1373D4B-2E9A-0B69-E053-4EBD850AB55D","beginDate":"2021-04-30","endDate":null,"createdBy":"KEARNSD","dateCreated":"2021-04-30","modifiedBy":"ONEDATA","dateModified":"2021-04-30","deletedIndicator":"No"},{"value":"1","valueDescription":"Single-Agent ICI","ValueMeaning":{"publicId":"7743025","version":"1","preferredName":"Single-Agent ICI","longName":"7743025","preferredDefinition":"Single-Agent Immune Checkpoint Inhibitor Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C77FBA01-9782-3B36-E053-4EBD850AD87D","latestVersionIndicator":"Yes","beginDate":"2021-07-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C77FBA01-979B-3B36-E053-4EBD850AD87D","beginDate":"2021-07-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2021-07-19","modifiedBy":"ONEDATA","dateModified":"2021-07-19","deletedIndicator":"No"},{"value":"2","valueDescription":"Combination ICI","ValueMeaning":{"publicId":"7741481","version":"1","preferredName":"Combination ICI","longName":"7741481","preferredDefinition":"Combination Immune Checkpoint Inhibitor Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C72E223C-0F57-0CF5-E053-4EBD850A169C","latestVersionIndicator":"Yes","beginDate":"2021-07-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2021-07-15","modifiedBy":"ONEDATA","dateModified":"2021-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C72E223C-0F70-0CF5-E053-4EBD850A169C","beginDate":"2021-07-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2021-07-15","modifiedBy":"ONEDATA","dateModified":"2021-07-15","deletedIndicator":"No"},{"value":"1","valueDescription":"Single Agent ICI","ValueMeaning":{"publicId":"7741482","version":"1","preferredName":"Single Agent ICI","longName":"7741482","preferredDefinition":"Single Agent Immune Checkpoint Inhibitor Therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C72E223C-0F7A-0CF5-E053-4EBD850A169C","latestVersionIndicator":"Yes","beginDate":"2021-07-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2021-07-15","modifiedBy":"ONEDATA","dateModified":"2021-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C72E223C-0F93-0CF5-E053-4EBD850A169C","beginDate":"2021-07-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2021-07-15","modifiedBy":"ONEDATA","dateModified":"2021-07-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6272107","version":"1","preferredName":"Therapeutic Procedure Stratification Code","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.:A symbol or combination of symbols which is assigned to the members of a collection.","longName":"C49236:C25689:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stratification","conceptCode":"C25689","definition":"The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9D9A6-C6E6-2131-E053-F662850A680C","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"ONEDATA","dateModified":"2018-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9D9A6-C6F7-2131-E053-F662850A680C","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"KEARNSD","dateModified":"2021-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Planned Cancer Therapy Type","type":"Preferred Question Text","description":"Planned Cancer Therapy Type","url":null,"context":"SWOG"},{"name":"CRF Text 1","type":"Alternate Question Text","description":"What is the planned type of immune checkpoint inhibitor therapy?","url":null,"context":"SWOG"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"What is the planned ICI regimen?","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9B0E6-5382-3803-E053-F662850A0070","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"KEARNSD","dateModified":"2021-07-19","changeDescription":"Added alternate question text and 2 permissible values - 04/30/21, DH; Added alternate question text and 2 permissible values - 07/15/21, DH; Added 1 permissible value - 07/19/21, DH;","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}